Reuters logo
BRIEF-Seres Therapeutics to initiate new SER-109 clinical study
2017年3月16日 / 上午11点29分 / 8 个月前

BRIEF-Seres Therapeutics to initiate new SER-109 clinical study

March 16 (Reuters) - Seres Therapeutics Inc

* Plans to initiate a new SER-109 phase 2 clinical study in patients with multiply recurrent clostridium difficile infection

* Plans to initiate a new SER-109 clinical study in approximately 320 patients with multiply recurrent C. Difficile infection Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below